CSF drug levels for children with acute lymphoblastic leukemia treated by 5 g/m2 methotrexate

Abstract A multicenter EORTC study was conducted in children with acute lymphocytic leukemia to determine whether 5 g/m 2 of methotrexate (MTX) (24 h i.v. infusion, four cycles) is an appropriate dosage for obtaining CSF drug concentrations approaching the critical cytotoxic level of 10 −6 M. A total of 193 cycles were analyzed for 58 patients. At the end of the 24 h infusion, the mean MTX serum level was 65.27 ± 33.11 μM; the mean CSF MTX level was 1.47 ± 1.1 μM; no significant difference in CSF MTX levels was observed between patients with ( n = 20) and those without i.v. Ara-C ( n = 38). The mean CSF MTX/serum MTX ratio was 0.029 ± 0.027. CSF drug concentrations greater than or equal to 10 −6 M were achieved in 81% of the courses. The highest level was 8.4 × 10 −6 M. Only 5% of patients failed to achieve this drug concentration in at least one cycle. No significant correlation was observed between blood and CSF MTX levels. Mean CSF MTX levels were comparable from one cycle to another.